Neurocysticercosis, the central nervous system's localised form of cysticercosis, is considered to be the leading cause of epilepsy in the developing world. In Europe, the disease is mainly imported and affects both immigrants and travellers. However, autochthonous cases of cysticercosis in low-endemic countries could also originate from Taenia solium carriers (migrants or travellers) who acquired taeniasis overseas. Management of cysticercosis is a challenge for European healthcare providers as they are often hardly aware of this infection and have little familiarity in managing this disease. This study provides a summary of recommendations concerning screening, diagnosis and management of cysticercosis and T. solium taeniasis in Europe drawn up by nine experts in migrant health and imported diseases with experience in cysticercosis and T. solium taeniasis.
Introduction
Cysticercosis occurs due to invasion of human or pig tissues at the metacestode larval stage of Taenia solium [1] . Taenia solium has a complex two-host life cycle [1] . Humans are the only definitive hosts, harbouring the adult tapeworm in the intestine without having significant symptoms (taeniasis) [2] . The adult tapeworm is acquired by eating raw or undercooked pork containing cysticerci [1] . Adult tapeworms have a life span of some years during which they produce millions of eggs which are intermittently released in the environment with the faeces [1] . Humans and pigs acquire cysticercosis by ingesting T. solium eggs through the faecal-oral route [1] . After ingestion, embryos contained in the eggs are released and cross the intestinal mucosa. They are then transported by the circulatory system and dispersed throughout the body, producing cysts mainly in the central nervous system (CNS) and in the striated muscles [1] . Human infection frequently results from ingesting T. solium eggs released by themselves (autoinfestation) or by another tapeworm carrier living in close contact or involved in the preparation of food [3] . In humans, the CNS is a frequent localisation of cysts which thus cause neurocysticercosis (NCC) [1] . NCC is considered the most frequent and preventable cause of epilepsy in the developing world, resulting in around 30% of epilepsy cases [4, 5] . In high-resource regions such as Europe, cysticercosis is mainly imported currently and affects immigrants and travellers [6] . However, autochthonous cases of cysticercosis in low-endemic countries could also originate from T. solium carriers (migrant or traveller) who acquired taeniasis overseas [3] ; thus, identifying and treating cases of taeniasis may prevent cases of cysticercosis. Management of cysticercosis is a challenge for European healthcare providers, as they are often poorly aware of this infection and have little familiarity in managing the disease [6] .
The objective of this document is to provide a summary of recommendations concerning screening, a See Acknowledgements for The COHEMI Project Study Group. diagnosis and management of cysticercosis and T. solium taeniasis in Europe in order to improve the quality of cysticercosis management in non-endemic or low-endemic areas.
Methods
Within the COHEMI (COordinating resources to assess and improve HEalth status of MIgrants from Latin America) project, under the auspices of the European Commission, an international and interdisciplinary expert group was created [7] . One of COHEMI's general objectives was the evaluation of care strategy for cysticercosis/epilepsy and the production of a series of systematic reviews on its epidemiology, management, treatment and diagnostic tools [4, 6, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] .
A panel of nine researchers with expertise in migrant health and imported diseases, with specific experience in cysticercosis and T. solium taeniasis reviewed the literature, evaluated and discussed the evidence and prepared a consensus-based final report with recommendations.
Definitions
Case definition of cysticercosis:
• See Table 1 .
Case definition of T. solium taeniasis:
• Confirmed case of taeniasis: laboratory-based diagnosis of taeniasis without species identification
• Probable case of taeniasis: reliable history of self-diagnosis by finding or reporting expelled tapeworm proglottids
• Confirmed case of T. solium taeniasis: confirmed case of taeniasis with species identification
Grading of evidence
In creating guidelines, the panel followed the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system [19] .
• Ia: systematic review or meta analysis of randomised controlled trials (RCTs)
• Ib: at least one RCT • IIa: at least one well-designed controlled study without randomisation
• IIb: at least one well-designed quasi-experimental study, such as cohort study
• III: well-designed non-experimental descriptive studies, such as comparative studies, correlation studies, casecontrol studies and case series 
Results and recommendations
Who should be screened for cysticercosis?
In theory, screening for cysticercosis in completely asymptomatic subjects could be useful in people at risk for NCC to intercept infected subjects and improve their management and clinical outcome early. However, there is no evidence in favour of a screening for asymptomatic people [20] . From the scarce information on natural evolution of cysticercosis, most infected subjects will never develop symptoms [21] . Moreover, considering parenchymal NCC, its most common form, there is no evidence that treating an asymptomatic subject harbouring a live parasite will reduce the probability for neurological symptoms in future.
Therefore, according to classical criteria, to evaluate the utility of a screening programme, if the answer to the question: 'Does treatment at the presymptomatic stage of a disease affect its course and prognosis?' is not clearly 'yes', then there is no case for screening [22] .
However, some presumed asymptomatic individuals may not be truly asymptomatic. The duration of the disease at the time of seeking medical care may be longstanding in patients with NCC and the median diagnostic delay ranges between 1 year in South Africa and 3.5 months in the United States [23] . Moreover, treatment of other conditions using antiparasitic drugs such as praziquantel (PZQ) or albendazole (ABZ) may result in adverse reactions during treatment in case of unrecognised cysticercosis (seizures or intracranial hypertension in case of cerebral cysts and ocular inflammation in case of ocular localisation). Therefore, investigating the presence of unrecognised signs or symptoms compatible with cysticercosis may be warranted in people at high risk of cysticercosis and in subjects with possible exposure in an endemic country who are undergoing treatment with antiparasitic drugs such as PZQ and ABZ (which may result in adverse reactions during treatment in case of unrecognised cysticercosis).
Grading of evidence: IV.
Recommendations: A clinical assessment to investigate unrecognised compatible symptoms of cysticercosis (history of convulsions and/or other compatible neurological signs or symptoms) and physical examination to detect subcutaneous nodules compatible with cysticercosis are recommended in subjects at high risk for cysticercosis such as
• Confirmed T. solium taeniasis cases;
• Household and daily contacts of confirmed T. solium taeniasis cases;
• Family members of cysticercosis cases who are likely to have been exposed to the same environment as the index case.
The same approach could be recommended for subjects with possible exposure in an endemic country before undergoing treatment with antiparasitic drugs such as PZQ and ABZ which may cause adverse reactions in case of unrecognised cysticercosis.
Subjects with compatible signs or symptoms should be fully assessed including appropriate brain imaging (CT scan and/or MRI; Appendix 1).
Grading of recommendations: D.
How to diagnose cysticercosis
In 1996, a group of experts developed a set of diagnostic criteria for cysticercosis that was updated for NCC in 2001, reviewed in 2012 and revised in 2016 [24] [25] [26] . The updated set of criteria includes absolute, neuroimaging and clinical/exposure criteria [26] . Absolute criteria include histological confirmation of parasites, evidence of subretinal cysts and demonstration of the scolex within a cyst. Neuroimaging criteria are categorised as major (cystic lesions without scolex, enhancing lesions, multilobulated cysts in the subarachnoid space and calcifications), confirmative (resolution of cysts after cysticidal drug therapy, spontaneous resolution of single enhancing lesions, and migrating ventricular cysts on sequential neuroimaging studies) and minor (hydrocephalus and leptomeningeal enhancement). Clinical/exposure criteria include detection of anticysticercal antibodies or cysticercal antigens by well-standardised tests, systemic cysticercosis, evidence of a household Taenia carrier, suggestive clinical manifestations and residency in endemic areas. The interpretation and combination of the criteria result in two degrees of diagnostic certainty: definitive and probable. Recently, a modified version of the 2001 criteria [24] was published by another group [27] . New criteria proposed in this study were tested using 93 previously diagnosed cases of NCC (all types) and 93 controls in whom diagnosis was ruled out and found to be similar to the existing set of diagnostic criteria by Del Brutto et al. [24, 28] . However, the validity of their modified set has not yet been assessed by a prospective study. Moreover, inclusion of antibody detection by ELISA as a major contributor to diagnosis may affect the specificity of these criteria as most commercially available ELISAs cross-react with other frequent cestode infections such as hymenolepiasis and hydatid disease [29] .
Even if formal diagnostic criteria exist, the diagnosis of cysticercosis still represents a challenge, especially in nonendemic areas such as Europe, where healthcare providers are hardly aware of the disease [6] and the level of expertise required for interpretation of neuroimaging is sometimes lacking.
Grading of evidence: IIb.
Recommendations: The use of the widely accepted and recently revised, diagnostic criteria (Table 1 ) [26] is advised for the diagnosis of NCC.
Grading of recommendations: B.
Who should be screened for Taenia solium taeniasis?
Intestinal taeniasis causes mostly non-specific and rarely noticeable symptoms [30] . Identification and treatment of subjects with T. solium taeniasis are important because these subjects may transmit cysticercosis to their contacts. In endemic areas, about 15-25% of NCC patients have a tapeworm or a previous history of taeniasis [30] [31] [32] . In Europe, intestinal taeniasis was found in 0-3.8% of patients with autochthonous and imported cysticercosis, respectively [6] . In the United States, 21% patients with NCC had a tapeworm carrier among asymptomatic household contacts [33] and this percentage increased to 45% in a study that considered only households of NCC patients aged 3 years or younger [34] . Finally, the presence of taeniasis in patients with NCC has been associated with increased severity of cerebral infestation [35] . The chance of finding a tapeworm in a patient with clinical manifestations, or in his household contacts, depends on how long the subject has been exposed in an endemic region and how much time has passed after immigrating from an endemic region. Most tapeworms probably die before the 3 to 5-year NCC pre-patent period [36] . Hence, the yield of screening for T. solium is expected to be quite low in most NCC cases in non-endemic areas. Screening for taeniasis should focus on individuals with live parenchymal cysts or enhancing lesions and their household members. Detecting tapeworm carriers is important because they can transmit cistycercosis by disseminating viable T. solium eggs [36] . The diagnostic test (see recommendations in paragraph 4.4), even if it has a low sensitivity, is not expensive.
Grading of evidence: III. Recommendations: Testing for T. solium taeniasis is recommended in the following subjects:
• Patients with cysticercosis and live parenchymal cyst or enhancing lesions
• Household and daily contacts of patients with cysticercosis, especially if a recent and/or local transmission is suspected (children, patients not exposed in endemic countries, patients with viable cysticerci)
• Subjects presenting a reliable history of proglottids expulsion within the last year (voiding from the anus, spontaneous or with faeces, of a noodle like piece of worm) Grading of recommendations: D.
How to diagnose Taenia solium taeniasis
Some problems hamper the diagnosis of T. solium infection: the lack/unspecificity of symptoms, the poor sensitivity of parasitological investigations and the morphological and antigenic similarity between T. solium and other Taenia spp. (T. saginata and T. asiatica).
As expulsion of tapeworm proglottids/eggs does not occur daily, diagnosis by coprology is difficult [1] . Coprology for taeniasis includes both macroscopic (for detection of proglottids) and microscopic examination (for detection of eggs) [32] . The reported sensitivity of microscopy ranges from 0% to 59% [37, 38] . An inexpensive and useful tool to support the diagnosis of 'self-detected' taeniasis is documenting the history of proglottid expulsion over the past few months or a year [39] .
Morphological identification through examination of scolex or stained mature proglottids (Table 2) is the most common laboratory procedure to identify the Taenia species. Morphological identification has several limits. The scolex is rarely available, the staining of proglottids is a laborious procedure and tapeworms may present some abnormalities or may be damaged, making identification difficult [32] . A purge with electrolyte-polyethylene glycol salt (EPS), 2 h before and 2 h after niclosamide treatment, has improved recovery of the scolex and the quality of the expelled proglottids [40] .
Three other ways to differentiate Taenia species are enzyme electrophoresis (glucose phosphate isomerase zymogrammes), molecular methods (different types of polymerase chain reaction, PCR) [32] and Coproantigen Enzyme Linked Immune Assay (CoAg-ELISA).
A T. solium species-specific [41] CoAg-ELISA shows high sensitivity (84.5-98%) and specificity (99%) [42, 43] . Unfortunately, it is experimental, not commercially available and rarely available except to those working in this field. Similarly, neither enzyme electrophoresis nor PCR is available in most laboratories.
Grading of evidence: III.
Recommendations:
The following tools are recommended for the diagnosis of T. solium taeniasis:
• Investigating the history of proglottids expulsion within the past year, with the support of visual materials to help the subject identify the proglottids
• Microscopic and macroscopic examination of stool samples collected on three different days
• Taenia species identification should always be performed, especially in subjects exposed to T. solium in The eggs of T. solium, T. saginata and T. asiatica cannot be distinguished morphologically.
highly endemic countries (Latin America, Asia and Africa). In such cases, if only morphological identification is available, a purge with EPS 2 h before and 2 h after the treatment may improve the recovery of the scolex and quality of the expelled proglottids. Patients should be provided with a container and asked to collect their faeces in the first 24 h after purge. Grading of recommendations: D.
How to treat cysticercosis
General principles and precautions.
• Treatment for NCC must be individualised based on the number and location of lesions, as well as viability of the parasites within the nervous system
• Patients with NCC should ideally be managed by a multidisciplinary team of healthcare professionals (such as specialists in neurology, infectious diseases, neurosurgery, neuroradiology and paediatrics)
• Therapeutic measures include symptomatic medication, antiparasitic drugs and surgery
• Antiparasitic drug treatment is never an urgent need, precaution is indicated, especially in patients with intracranial hypertension secondary to NCC
• Patients should first be stabilised if intracranial hypertension is present (by placing a ventricle-peritoneal shunt) and/or if other symptoms such as epilepsy and headache are present (using antiepileptic and analgesic drugs)
• Before initiating antiparasitic treatment for NCC, the patient should be examined for particular locations and forms of the disease (presence of ocular cysticercosis, massive/encephalitic NCC, intraventricular NCC, cysts in other risk areas such as the brainstem) that may increase the risk of adverse events in case of antiparasitic treatment [44, 45] . According to a recent meta-analysis, ABZ is probably safe and effective in reducing both the number of cysts and long-term seizure risk (by 6.1%; 95% CI 0.3-11.9%) in patients with parenchymal NCC [46] . A meta-analysis showed clinical (increased rate of seizure-free period) and radiological benefit in treating solitary cysticercus granuloma with antiparasitic drugs (ABZ in majority of the cases) [47] .
Another meta-analysis found that the association of ABZ and corticosteroids is the most efficacious regimen and that it could prevent seizure recurrence and promote lesion resolution in a follow-up period of around 1 year [48] . The combination of ABZ and PZQ increased the parasiticidal effect in patients with multiple intraparenchymal cysticercosis cysts without increased side effects during a double-blind placebo-controlled phase-3 trial. The complete resolution of brain cysts at 6 months with MRI was achieved in 64% of the patients who received combined ABZ (15 mg/kg/day) plus PZQ (50 mg/kg/day) for 10 days, in 37% of those who received ABZ at the standard dosage (15 mg/kg/day) for 10 days and in 53% of patients who got ABZ at increased dosage (22.5 mg/kg/ day) for 10 days [49] . Complete cyst resolution was significantly associated with fewer seizures in the follow-up [49] .
Similar results were reported in a randomised, doubleblinded, placebo-controlled phase II evaluation of the pharmacokinetics of ABZ (15 mg/kg/day, for 10 days) and PZQ (50 mg/kg/day, for 10 days) in intraparenchymal brain cysticercosis. Cysticidal efficacy was strikingly higher in the combined ABZ-plus-PZQ group than in the ABZ-alone group (proportion of cysts resolved, 95% vs. 30%) [50] .
Current practice favours antiparasitic treatment in most patients with viable infections, after individual assessment and exclusion of high-risk situations (massive infections, intraventricular cysts and concomitant ocular cysticercosis) [51] . Another meta-analysis suggests that corticosteroids can speed resolution of lesions at 6-12 months and reduce the rate of seizures [52] . Between the second and the fifth day of antiparasitic treatment [53] , death of the parasites triggers a local inflammatory reaction which may precipitate further neurological symptoms (and even become fatal in rare cases). Therefore, some experts recommend that corticosteroids should be started a day before the onset of antiparasitic treatment and tapered in a period of 6-8 weeks or longer [53, 54] . An open-labelled randomised trial comparing 6 mg/day dexamethasone for 10 days with 8 mg/day for 28 days followed by a 2-week taper (enhanced steroids) suggested that increased dexamethasone dosage results in fewer seizures during the treatment period [55] . Dexamethasone reduces plasma concentration of PZQ [56] although the clinical impact of this interaction has never been properly assessed.
Both PZQ and ABZ should be taken with food. Possible side effects of PZQ include malaise, headache, dizziness, nausea (the tablets have a bitter taste), fever, urticaria or other allergic reactions, palpitations or arrhythmias, bloody diarrhoea and convulsions. Possible side effects of ABZ include hepatotoxicity, agranulocytosis, alopecia, headache, nausea/vomiting, urticaria and abdominal pain. Full blood cell count and hepatic function of patients receiving ABZ should be monitored [57] .
Concerning calcified intracranial cysticerci, increasing evidence demonstrates that perilesional oedema around a calcified lesion is associated with ongoing seizures [58] . Perilesional oedema may be responsible for seizure recurrence, recovering spontaneously within 4-6 weeks but sometimes experiencing repeated episodes. So far, there is no proven specific treatment for perilesional oedema episodes other than symptomatic therapy with antiseizures medication. However, anti-inflammatory measures (i.e. methotrexate) have been used in particular cases with apparent success [59] .
Grading of evidence: Ia. Recommendations:
• Treatment of NCC with antiparasitic drugs should be performed under medical supervision with concomitant steroid therapy, once an appropriate symptomatic treatment is well established (grading of recommendation D)
• Parenchymal NCC (in all stages, excluding calcified lesions) should be treated with ABZ 15 mg/kg/day in two doses (up to 400 mg twice a day) plus PZQ (50 mg/kg/day) both for 10 days (grading of recommendation A)
• In case of solitary cyst or granuloma, monotherapy with ABZ at the same dosage and duration may be sufficient
• Longer or repeated courses of antiparasitic treatment may be necessary since a single course may not be able to clear all cysts (grading of recommendation B)
• Corticosteroids should be used in conjunction with antiparasitic drugs (grade of recommendation A).
• Dexamethasone 8 mg/day for 28 days from the day before starting antiparasitic treatment followed by a 2-week taper is the preferred corticosteroid regimen (grading of recommendation A) Subarachnoid NCC. Extraparenchymal NCC, in particular basal subarachnoid NCC, should be recognised as a progressive condition associated with a severe prognosis. Control of mass effect and intracranial hypertension is the priority. Once the patient is stable, antiparasitic therapy should be initiated with appropriate care and continued for long periods with clinical, serological (antigen detection) and MRI follow-up. Monitoring of circulating parasite antigen in serum could be of great help in this type of NCC [60] . Grading of evidence: III.
Recommendations:
• Management of intracranial hypertension and hydrocephalus can be life-saving and is the priority in patients with extraparenchymal NCC. Many patients may benefit from placement of a ventriculoperitoneal shunt (grading of recommendation D)
• Antiparasitic drugs are recommended for an individualised duration of treatment based on imaging response. Long-term courses and repeated cycles are often needed (grading of recommendation D)
• Corticosteroids should always be associated with antiparasitic drugs to reduce subarachnoid inflammation. Generally, 1 mg/kg/day of prednisone or 0.2-0.4 mg/kg/day (with a maximum dose of 24 mg/day divided in 4 doses) of dexamethasone is administered 3 or 4 days before and during antiparasitic treatment and then tapered. Long-term corticosteroids therapy at lower doses is often required in patients with a ventricular shunt [61] (grading of recommendation D)
• Given its severity and rarity and the few available evidences, clinicians managing subarachnoid NCC should seek advice from an expert. Grading of recommendation: D.
Intraventricular NCC. In the past decade, availability of neuroendoscopical exploration and cyst removal using minimally invasive procedures has provided a safer and more efficacious approach for the treatment of ventricular NCC. However, there are no randomised treatment trials comparing the usefulness and safety of surgery with medical approaches. According to a review on this topic, neuroendoscopy or open microsurgery is indicated to remove cysts in case they are causing mass effect, CSF obstruction, in case of fourth ventricular cysts or if the diagnosis is uncertain [62] . Adhered cysts (usually degenerating cysts) should not be removed surgically as they may cause bleeding during the procedure. Grading of evidence: III. Recommendations:
• Emergency ventriculostomy or ventriculoperitoneal shunt (VPS) is indicated in case of acute hydrocephalus (grading of recommendation D)
• VPS placement is indicated in case of obstructive/communicating hydrocephalus (grading of recommendation D)
• Neuroendoscopy or open microsurgery is indicated to remove cysts in case they are causing mass effect, CSF obstruction, in case of fourth ventricular cysts or if the diagnosis is uncertain (grading of recommendation D)
• Medical treatment of intraventricular cysts with antiparasitic drugs and corticosteroid is an option primarily for adhered cysts, but there is no evidences to recommend it as a preferred regimen
• Given its severity and rarity and the few available evidences, clinicians managing intraventricular NCC should seek advice from an expert. Grading of recommendation: D.
Spinal NCC. Spinal NCC mostly has an extramedullary, subarachnoid localisation. Although some patients show focal symptoms, asymptomatic spinal invasion is also frequently found in patients with basal subarachnoid NCC.
It is unclear what the best treatment approach is for symptomatic spinal NCC [63] . Surgery may be needed in patients with symptoms due to mass effect on the spinal cord and those who require immediate relief of pressure.
In patients with asymptomatic spinal invasion, a non-surgical approach seems to be preferable [64] . Grading of evidence: III. Recommendations:
• Management of spinal extramedullary NCC is performed primarily with corticosteroids and antiparasitic treatment. This is similar to the subarachnoid disease in the brain (grading of recommendation D)
• Surgery may be needed in case patients show symptoms due to mass effect on the spinal cord and need immediate relief of pressure (grading of recommendation: D)
• Management of spinal intramedullary NCC is performed preferably with antiparasitic drugs and corticosteroids (grading of recommendation: D)
• If resources permit, a spine MRI should be performed on subjects with basal subarachnoid NCC (grading of recommendation: D)
Ocular cysticercosis. Cysticerci may appear in the anterior and posterior chamber of the eye. Vitreous and retinal cysticercosis will most likely result in significant reduction of visual capacity in the patient. Ocular cysticercosis is usually managed by surgery [65] . Unrecognised ocular cysticercosis could lead to ocular damage if antiparasitic treatment for NCC is started [66] . Grading of evidence: III.
Recommendations: The management of ocular cysticercosis is usually by surgery (grading of recommendation D).
Cysticercosis in other localisations. Subcutaneous or muscular cysticercosis can be found occasionally, mostly by questioning the patient. These cysts provide a possibility for histological confirmation of diagnosis. Clinically, subcutaneous or muscular NCC is not a significant problem. Cardiac cysticercosis has been reported but so far without producing clinical manifestations.
Follow-up
Neuroimages show degeneration and/or resolution of active parenchymal lesions after 3-6 months of antiparasitic treatment [46] . Antibody persistence is of little use in follow-up as enzyme-linked immunoelectrotransfer blot (EITB) positivity persists in most (77%) of the cured patients 1 year after treatment [67] . Detection of circulating antigen ELISA in serum could be helpful to follow up patients after treatment as it is able to demonstrate the presence of viable cysts and a relatively fast decrease in antigen levels is expected after successful antiparasitic treatment [68] . However, there are few data on its use, especially concerning how well a non-detectable level predicts successful cure and its performance in CSF compared to serum.
Grading of evidence: III. Recommendations:
• Follow-up of parenchymal NCC should initially include neuroimages performed every 3-6 months, and detection of cysticercus antigen in serum if the test is available (grading of recommendation D)
• A stricter follow-up (every 3 months or closer in case of clinical deterioration) based on both neuroimages (MRI) and cysticercus antigen in serum is needed for patients with subarachnoid NCC to guide treatment. In these cases, the ideal end-point is resolution of cystic lesions; an acceptable end-point is stabilisation of lesions in those that do not resolve. Subarachnoid NCC can lead to distortion of the subarachnoid space and ongoing contrast-enhancement despite successful therapy (grading of recommendation: D).
Treatment of epilepsy in patients with NCC
Seizures usually respond very well to first-line antiepileptic drug (AED) monotherapy [69, 70] . The risk of seizure recurrence following an initial seizure in NCC is 50-80% in patients who discontinued AEDs [71] . Risk of recurrence of seizure during treatment with AED is highly variable (13-48% in patients with solitary cysticercus granuloma over a period of 6-12 months) and it is higher in patients with degenerating lesions compared to those with resolved lesions [71] . Only 15% of subjects with resolved single cysticercus granuloma had seizure recurrence after the discontinuation of AED [71] . In patients with resolved lesions, the presence of calcified residues represents the main risk factor for seizure recurrence. The mechanism by which the calcified lesions cause seizures or epilepsy is unknown but perilesional gliosis, perilesional oedema and the presence of hippocampal atrophy may play a role. [70, 71] . There are a few trials comparing various AEDs in people with NCC. The main drug interactions between AED and other drugs commonly used for treatment of NCC involve phenytoine (which decreases serum level of PZQ, prednisone and dexamethasone), phenobarbital (which decreases the level of prednisone and dexamethasone) and dexamethasone (which decreases the level of phenytoine) [72] . No evidence is available regarding the use of AEDs as prophylaxis for preventing seizures among people with symptoms other than seizures [73] .
Grading of evidence: III.
• About 85% § About 95% § † Symptoms possibly related to activation of cysticercosis were observed in one person among 10 173 people treated with praziquantel in Ecuador [77] .
‡ In order to improve the recovery of the scolex and the quality of the expelled proglottids, a purge with electrolyte-polyethylene glycol salt (EPS), 2 h before and 2 h after niclosamide treatment, can be applied [40] . §The efficacy has been assessed mainly in T. saginata taeniasis, using microscopic examination and/or clinical follow-up as test of cure that could have overestimated the efficacy. A recent study on treatment of Taenia solium taeniasis with niclosamide using Coproantigen-ELISA as test of cure found a cure rate of 77.9% (53/68) . A second treatment course with niclosamide cured 11/13 of patients that initially failed. Overall, niclosamide cured 64/66 (97%) patients [78] .
How to treat Taenia solium taeniasis
The main goals of the treatment of T. solium taeniasisis are to prevent new cases of human and porcine cysticercosis, impede the spread of cysticercosis in people and interrupt the life cycle of the parasite. Single patient treatment is recommended given the possibility of autoinfestation and the association with more severe form of NCC in subjects with taeniasis [35] .
Two drugs are available and widely used for the treatment of taeniasis: niclosamide and PZQ. The principal characteristics of the two drugs are reported in Table 3 .
Grading of evidence: IIa. Recommendations:
• Confirmed and probable case of taeniasis should be treated with niclosamide or PZQ at standard dosages (see Table 3 ).
• Clinicians should be aware that PZQ may sporadically cause symptoms (i.e. seizures) in patients with unrecognised asymptomatic NCC due to inflammatory reaction around the damaged cysticerci. If PZQ is used, recommendations reported in Appendix 1 have to be followed.
• Taenia species identification should always be performed, especially in subjects exposed to T. solium in highly endemic countries (Latin America, Asia and Africa).
After therapy, the patient should be followed up to confirm the efficacy of treatment by:
• Questioning the history of proglottids expulsion after ABZ, albendazole; PZQ, praziquantel; MRI, magnetic resonance imaging; CT, computed tomography.
*This category of subjects is not at increased risk of cysticercosis, but is at risk of having an adverse reaction (i.e. seizures) after receiving treatment with albendazole or praziquantel in case of unrecognised cysticercosis. # Brain MRI and CT scan are both useful to detect neurocysticercosis as MRI has an higher sensitivity to detect viable extraparenchymal neurocysticercosis, while CT scan has a better performance in detecting calcifications [26, 75] .
